Anton Juncaj
Hematology & Oncology · Savannah, GANPI 1649831314
Payments from drug & device makers
Across 103 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$548
- Genentech USA, Inc.$225
- Adaptive Biotechnologies Corporation$183
- AstraZeneca$166
- Merck$133
- Johnson & Johnson$131
- plus $925 from 28 others
What the payments were for
- Food & beverage$2,25498%
- Education$562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $548 |
| Genentech USA, Inc. | 10 | $225 |
| Adaptive Biotechnologies Corporation | 2 | $183 |
| AstraZeneca(2 entities) | 7 | $166 |
| Merck | 5 | $133 |
| Johnson & Johnson | 7 | $131 |
| AVEO Pharmaceuticals, Inc. | 4 | $104 |
| Astellas Pharma US Inc | 4 | $82 |
| Beigene USA, Inc. | 3 | $71 |
| E.r. Squibb & Sons, L.L.C. | 2 | $62 |
| AbbVie | 2 | $52 |
| Eisai Inc. | 2 | $48 |
| Amgen | 2 | $38 |
| Legend Biotech USA Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Deciphera Pharmaceuticals Inc. | 2 | $32 |
| Geron Corporation | 1 | $32 |
| Foundation Medicine, Inc. | 2 | $29 |
| Coherus Oncology, Inc. | 1 | $27 |
| Genmab U.S., Inc. | 1 | $26 |
| Boston Scientific | 1 | $24 |
| Sanofi | 1 | $23 |
| GSK | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Bayer | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- clonoSEQ$150
How this compares
$2,311 in reported general payments places this provider in the 30th percentile of 370 hematology & oncology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 16 | $227,264 |
| Morphine Sulfate ErMorphine Sulfate | 20 | $380 |
| Hydroxyurea | 15 | $375 |
| Acyclovir | 20 | $299 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $293 |
| Dexamethasone | 21 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $82 | $227,26416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Savannah
- Mark TaylorSavannah$3.7M
- Alison SpellmanSavannah$2.2M
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Amelia ZelnakCumming$4.4M
- Conor SteuerAtlanta$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.